BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc > What to you guys think....?

<< Previous

Bullboard Posts

Next >>

Comment by Minrayon Jul 10, 2022 8:15am

95 Views

Post# 34813540

RE:What to you guys think....?

May be but they need to post an update about their meeting with the FDA, held in June, to seek approval to test their drug in the USA. They may then see the SP rise well above the high teens and/or low 20's.

<< Previous

Bullboard Posts

Next >>

Bitcoin company adds convenience of modern banking